Real time Form 13D and 13G transaction reports:
- Schedule 13D must be filed within ten days after a person or an organization acquires beneficial ownership of more than 5% of a voting class of a company's equity securities.
- Due to inconsistent filing format, it is highly recommended that you read the orignal filing form.
- Shares have beem adjusted for stock split.
"Insiders might sell their shares for any number of reasons, but they buy them for only one: they think the price will rise"
- Peter Lynch
What is insider trading>>
- Peter Lynch
What is insider trading>>
| Reported DateTime | Transaction Date | Type | Company Symbol | Filed By Symbol | Shares Owned % Owned | Shares Vs. Prev Report | View |
| 2025-11-14 6:33 pm Purchase | 2025-09-30 | 13G | Pelthos Therapeutics Inc. PTHS | Ikarian Capital, LLC | 186,408 6.100% | 186,408 (New Position) | Filing History |
| 2025-11-14 6:30 pm Sale | 2025-09-30 | 13G | Aethlon Medical, Inc. AEMD | Ikarian Capital, LLC | 15,366 2.000% | -0 (-0.00%) | Filing History |
| 2025-11-14 6:28 pm Purchase | 2025-09-30 | 13G | iBio, Inc. IBIO | Ikarian Capital, LLC | 1,151,051 4.990% | 551,138 (+91.87%) | Filing History |
| 2025-11-14 6:28 pm Purchase | 2025-09-30 | 13G | Relmada Therapeutics, Inc. RLMD | Ikarian Capital, LLC | 3,543,359 4.800% | 3,543,359 (New Position) | Filing History |
| 2025-11-14 6:26 pm Sale | 2025-09-30 | 13G | Avalo Therapeutics, Inc. AVTX | Ikarian Capital, LLC | 711,967 3.800% | -479,990 (-40.27%) | Filing History |
| 2025-11-07 4:30 pm Unchanged | 2025-10-31 | 13G | Spruce Biosciences, Inc. SPRB | Ikarian Capital, LLC | 121,356 11.400% | 0 (Unchanged) | Filing History |
| 2025-10-08 11:04 am Purchase | 2025-10-06 | 13G | Spruce Biosciences, Inc. SPRB | Ikarian Capital, LLC | 121,356 21.600% | 121,356 (New Position) | Filing History |
| 2025-10-07 4:15 pm Purchase | 2025-09-30 | 13G | Tenax Therapeutics, Inc. TENX | Ikarian Capital, LLC | 967,600 21.200% | 967,600 (New Position) | Filing History |
| 2025-08-14 4:20 pm Purchase | 2025-06-30 | 13G | Forte Biosciences, Inc. FBRX | Ikarian Capital, LLC | 617,667 4.990% | 8,442 (+1.39%) | Filing History |
| 2025-05-15 5:33 pm Purchase | 2025-03-31 | 13G | Avalo Therapeutics, Inc. AVTX | Ikarian Capital, LLC | 1,191,957 9.990% | 221,598 (+22.84%) | Filing History |
| 2025-05-15 5:26 pm Purchase | 2025-03-31 | 13G | Traws Pharma, Inc. TRAW | Ikarian Capital, LLC | 589,502 9.990% | 195,247 (+49.52%) | Filing History |
| 2025-05-15 5:26 pm Purchase | 2025-03-31 | 13G | Cumberland Pharmaceuticals Inc. CPIX | Ikarian Capital, LLC | 730,932 4.900% | 730,932 (New Position) | Filing History |
| 2025-02-14 1:25 pm Purchase | 2024-12-31 | 13G | Avenue Therapeutics, Inc. ATXI | Ikarian Capital, LLC | 140,000 6.800% | 140,000 (New Position) | Filing History |
| 2025-02-14 1:22 pm Purchase | 2024-12-31 | 13G | Galera Therapeutics, Inc. GRTX | Ikarian Capital, LLC | 7,538,690 9.990% | 7,538,690 (New Position) | Filing History |
| 2025-02-14 1:21 pm Purchase | 2024-12-31 | 13G | Aethlon Medical, Inc. AEMD | Ikarian Capital, LLC | 15,366 8.700% | 15,366 (New Position) | Filing History |
| 2025-02-14 1:18 pm Purchase | 2024-12-31 | 13G | Traws Pharma, Inc. TRAW | Ikarian Capital, LLC | 394,255 9.990% | 394,255 (New Position) | Filing History |
| 2025-02-14 1:15 pm Purchase | 2024-12-31 | 13G | Forte Biosciences, Inc. FBRX | Ikarian Capital, LLC | 609,225 9.500% | 609,225 (New Position) | Filing History |
| 2025-02-14 1:09 pm Purchase | 2024-12-31 | 13G | Channel Therapeutics Corporation CHRO | Ikarian Capital, LLC | 44,085 7.300% | 44,085 (New Position) | Filing History |
| 2025-02-14 1:07 pm Purchase | 2024-12-31 | 13G | Alpha Cognition Inc. Common Stock ACOG | Ikarian Capital, LLC | 967,867 6.000% | 967,867 (New Position) | Filing History |
| 2024-11-14 8:51 pm Purchase | 2024-09-30 | 13G | TRACON Pharmaceuticals, Inc. TCON | Ikarian Capital, LLC | 133,404 3.900% | 133,404 (New Position) | Filing History |